A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

PHASE1TerminatedINTERVENTIONAL
Enrollment

189

Participants

Timeline

Start Date

May 14, 2018

Primary Completion Date

July 18, 2024

Study Completion Date

July 18, 2024

Conditions
LymphomaMultiple MyelomaAcute Myeloid LeukemiaDiffuse Large B-Cell Lymphoma
Interventions
DRUG

Maplirpacept (PF-07901801)

maplirpacept (PF-07901801) will be administered by intravenous infusion at ranging doses, as determined from sequential dosing cohorts.

DRUG

Azacitidine

intravenous (IV) or subcutaneous (SC) daily for 7 days, repeated every 4 weeks

DRUG

Venetoclax

orally daily for each day of each cycle (first 7 doses taken in clinic). The ramp-up and target dose of venetoclax will be adjusted per the package insert in subjects who are taking concomitant moderate or strong CYP3A4 inhibitors or posaconazole

DRUG

Carfilzomib

Days 1, 8, and 15 of 28-day cycles; starting dose IV given on Cycle (C) 1 Day (D) 1, and if tolerated, then increased dose via IV given starting on C1D8 and subsequent doses thereafter.

DRUG

Dexamethasone

starting dose via IV on Days 1, 8, 15, and increased dose via IV on 28-day cycles

DRUG

Anti-CD20 Targeting agent

Days 1,8,15, and 22 of the first 28-day cycle and then on Day 1 of subsequent 21-day cycles. The anti-CD20 targeting agent will be administered for a total of eight doses, and then Cohort F1, F2 and F3: TTI-622 + isatuximab, carfilzomib and dexamethasone Cohort C1, C2 and C3: TTI-622 + Carfilzomib and Dexamethasone will be continued as single-agent therapy.

DRUG

Isatuximab

"F1: IV dose C0D1, C0D8, C0D15 and C0D22 (lead in phase);weekly during Cycle 1; Cycle 2 and beyond will be administered on Days 1 and 15 (Q2W).~F2 and F3: IV dose C0D1 and C0D8 (lead in phase); C1D1, C1D8, C1D15 and C1D22; Cycle 2 and beyond will be administered on days 1 and 15 (Q2W). Carfilzomib: IV dose on days 1 and 2 of cycle 1; then increased IV dose on days 8, 9, 15, and 16 of cycle 1; cycle 2 and beyond: increased IV dose on days 1, 2, 8, 9, 15, and 16. Dexamethasone IV or PO on days 1, 2, 8, 9, 15, 16, 22, and 23 starting cycle 1."

Trial Locations (62)

10021

Memorial Sloan Kettering Cancer Center - David H. Koch Center, New York

10065

Memorial Sloan Kettering Cancer Center (Outpatient Center), New York

Memorial Sloan Kettering Cancer Center, New York

10467

Montefiore Medical Center, The Bronx

10604

Memorial Sloan Kettering Cancer Center at Westchester, Harrison

11101

Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy, Long Island City

11553

Memorial Sloan Kettering Cancer Center at Nassau, Uniondale

11725

Memorial Sloan Kettering Cancer Center at Commack, Commack

14263

Roswell Park Cancer Institute, Buffalo

15224

West Penn Hospital, Pittsburgh

19107

Sidney Kimmel Cancer Center, Clinical Trials Organization, Philadelphia

Sidney Kimmel Cancer Center, Research Support Services, Philadelphia

Thomas Jefferson University - Clinical Research Institute, Philadelphia

Thomas Jefferson University Investigational Drug Services, Philadelphia

Thomas Jefferson University, Investigational Drug Service, Philadelphia

Thomas Jefferson University, Medical Oncology, Philadelphia

Thomas Jefferson University, Philadelphia

19713

Christiana Care Health Services, Newark

Christiana Care Hematology Oncology - Helen F Graham Cancer Center, Newark

Medical Oncology Hematology Consultants, PA, Helen F. Graham Cancer Center, Newark

19718

Christiana Care Health Services - Christiana Hospital, Newark

20007

Georgetown University Medical Center, Washington D.C.

27103

Novant Health Cancer Institute - Research Office, Winston-Salem

Novant Health Cancer Institute Hematology - Forsyth, Winston-Salem

Novant Health Forsyth Medical Center, Winston-Salem

28204

Novant Health Cancer Institute - Research Office, Charlotte

Novant Health Cancer Institute Hematology - Charlotte, Charlotte

Novant Health Presbyterian Medical Center, Charlotte

29605

Prisma Health, Institute for Translational Oncology Research, Clinical Research Unit, Greenville

Prisma Health-Upstate Cancer Institute, Greenville

30342

Blood and Marrow Transplant Group of Georgia, Atlanta

Northside Hospital, Atlanta

33606

Tampa General Hospital Cancer Institute, Tampa

Tampa General Hospital, Tampa

37920

University of TN Medical Center, Knoxville

40207

Norton Cancer Institute, St Matthews Campus, Louisville

Norton Cancer Institute, St. Matthews Campus, Attn. Becky Champion, PharmD, Louisville

Norton Diagnostic Center-Dupont (PET Scans), Louisville

Norton Women & Children's Hospital, Louisville

44718

Gabrail Cancer Center Research, Canton

46237

Indiana Blood & Marrow Transplantation, Indianapolis

Indiana Blood and Marrow Transplantation-Administrative Offices, Indianapolis

Indiana Blood and Marrow Transplantation-Clinic, Indianapolis

48109

University of Michigan Hospitals, Ann Arbor

University of Michigan, Ann Arbor

48201

Barbara Ann Karmanos Cancer Institute, Detroit

48334

Karmanos Cancer Institute Weisberg Cancer Treatment Center, Farmington Hills

77030

Oncology Consultants P.A., Houston

The University of Texas MD Anderson Cancer Center, Houston

80218

Colorado Blood Cancer Institute, Denver

HealthONE Presbyterian/St. Luke's Medical Center, Denver

90033

Keck Hospital of USC, Los Angeles

LAC+USC Medical Center, Los Angeles

USC/Norris Comprehensive Cancer Center, Los Angeles

91105

Keck Hospital of USC Pasadena, Pasadena

98104

Swedish Cancer Institute, Seattle

98122

Swedish Medical Center, Seattle

07920

Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge

07932

Summit Medical Group Cancer Center, Florham Park

07748

Memorial Sloan Kettering Cancer Center at Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

Memorial Sloan Kettering Cancer Center at Montvale, Montvale

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03530683 - A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma | Biotech Hunter | Biotech Hunter